MOTS-C (10 mg Vial) Dosage Protocol

In this Protocol

Quickstart Highlights

MOTS-c is a 16–amino-acid mitochondrial-derived peptide (MDP) that acts as a metabolic regulator, primarily through AMPK activation[1][2]. Preclinical studies show it enhances insulin sensitivity, promotes fat oxidation, improves exercise capacity, and counters age-related metabolic decline[1][4]. No clinical trials have been completed in humans to date[8]. This educational protocol presents a once-daily subcutaneous approach with gradual titration.

  • Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
  • Typical daily range: 200–1,000 mcg once daily (gradual titration over 10 weeks).
  • Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U‑100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F) or below; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 7 days for best potency.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Week Daily Dose (mcg) Units (per injection) (mL)
Weeks 1–2 200 mcg (0.2 mg) 6 units (0.06 mL)
Weeks 3–4 400 mcg (0.4 mg) 12 units (0.12 mL)
Weeks 5–6 600 mcg (0.6 mg) 18 units (0.18 mL)
Weeks 7–8 800 mcg (0.8 mg) 24 units (0.24 mL)
Weeks 9–10+ 1,000 mcg (1.0 mg) 30 units (0.30 mL)

Frequency: Inject once daily subcutaneously[7]. This schedule uses the largest practical dilution (3.0 mL) to maintain per‑injection accuracy. Stay at each dose level for approximately 2 weeks before increasing, and monitor for any adverse reactions[7].

For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake vigorously).
  4. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  5. Use within 7 days for optimal potency[7].
Important: This guide is for educational purposes only and is not medical advice. MOTS-c is an experimental compound for research use only. Not for human consumption.

Supplies Needed

Plan based on an 8–12 week daily protocol with gradual titration.

  • Peptide Vials (MOTS-C, 10 mg each):
    • 8 weeks ≈ 3 vials
    • 12 weeks ≈ 6 vials
    • 16 weeks ≈ 9 vials
  • Insulin Syringes (U‑100):
    • Per week: 7 syringes (1/day)
    • 8 weeks: 56 syringes
    • 12 weeks: 84 syringes
    • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
    • 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
    • 12 weeks (6 vials): 18 mL → 2 × 10 mL bottles
    • 16 weeks (9 vials): 27 mL → 3 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.
    • Per week: 14 swabs (2/day)
    • 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
    • 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
    • 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
MOTS C 10mg vial - MOTS C dosage protocol
View Supplier
Insulin Syringes for subcutaneous peptide injection
View Supplier
Bacteriostatic water 10ml for peptide reconstitution
View Supplier
EasyTouch alcohol prep pads for injection site sterilization
View Supplier

 

Protocol Overview

Concise summary of the once‑daily regimen.

  • Goal: Support metabolic homeostasis, insulin sensitivity, and age-related physical performance based on preclinical evidence[1][2][4].
  • Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
  • Dose Range: 200–1,000 mcg daily with gradual titration over 10 weeks.
  • Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); avoid repeated freeze–thaw.

Dosing Protocol

Suggested daily titration approach based on animal-to-human extrapolation.

  • Start: 200 mcg daily for 2 weeks.
  • Titration: Increase by ~200 mcg every 2 weeks: 400 mcg (Weeks 3–4), 600 mcg (Weeks 5–6), 800 mcg (Weeks 7–8).
  • Target: Up to 1,000 mcg (1.0 mg) daily by Weeks 9–10+ if well tolerated[7].
  • Frequency: Once per day (subcutaneous).
  • Cycle Length: 8–12 weeks; optional extension to 16 weeks.
  • Timing: Any consistent time; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality and potency.

  • Lyophilized: Store at −20 °C (−4 °F) or below in dry, dark conditions; include desiccant if available to minimize moisture exposure.
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); peptide degrades rapidly at room temperature (~25% activity loss after 24 hours at 4 °C)[7]. Use within 7 days for best potency.
  • Aliquoting: Prepare single-use aliquots and freeze at −20 °C (−4 °F) if needed; avoid freeze–thaw cycles.
  • Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes for each injection; dispose in a sharps container[11].
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and prevent lipohypertrophy[11].
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Document daily dose, injection site, and any observations to maintain consistency.
  • Discontinue use and consult a medical professional if any concerning symptoms arise.

How This Works

MOTS-c functions as a metabolic “stress signal” that helps optimize energy usage during nutrient stress or exercise[2]. Its primary mechanism is AMPK activation through inhibition of the folate cycle, causing accumulation of AICAR (an AMP analog)[1][2]. Activated AMPK shifts cells into an energy-efficient mode – enhancing glucose uptake, fatty-acid oxidation, and mitochondrial respiration while downregulating fat storage and gluconeogenesis[2].

MOTS-c can also translocate to the cell nucleus under stress conditions and upregulate antioxidant and stress-response genes[2]. This retrograde signaling from mitochondria to nucleus increases expression of cytoprotective enzymes, helping cells cope with oxidative stress. Research indicates MOTS-c may also modulate mTOR and inflammatory pathways, contributing to lifespan and healthspan effects[10]. Its actions resemble those of exercise and metformin at a cellular level[2], making it of great interest for metabolic disorders, obesity, and aging research.

Potential Benefits & Side Effects

Observations from preclinical literature (no human clinical trials completed to date)[8]:

  • Metabolic Health: Improves insulin sensitivity and glucose metabolism in mouse models; prevents diet-induced insulin resistance[1][7].
  • Weight & Fat Reduction: Prevents obesity and reduces visceral fat in obese mice through increased energy expenditure and fat oxidation[1][7].
  • Post-Menopausal Metabolism: Mitigates metabolic decline in ovariectomized mice; prevents menopause-related fat gain and insulin resistance[3].
  • Physical Performance: Enhances exercise capacity and counters age-related frailty; old mice ran 2× longer on treadmill tests[4][7].
  • Organ Protection: Reduces liver fat accumulation, improves cardiac function, and may support cognitive function in preliminary studies[2][7].
  • Bone & Immunity: Promotes osteoblast activity, inhibits osteoclast formation; modulates immune aging and protects pancreatic islet cells in autoimmune diabetes models[5][10].
  • Safety: No adverse effects reported in preclinical studies; human tolerability unknown. A modified analog (CB4211) showed good tolerability in a Phase 1 trial[7].

Note: These benefits have been demonstrated only in controlled research settings (mice or cells). Translation to humans requires clinical studies.

Lifestyle Factors

Complementary strategies for best outcomes based on MOTS-c’s metabolic mechanisms.

  • Pair with a balanced, protein-forward diet tailored to energy needs.
  • Combine resistance training and aerobic activity to reinforce metabolic adaptations and AMPK signaling[4][8].
  • Prioritize sleep (7–9 hours) and stress management to support mitochondrial health and recovery.
  • Consider intermittent fasting or caloric restriction, which may synergize with MOTS-c’s AMPK-mediated effects.

Injection Technique

General subcutaneous guidance from clinical best‑practice resources[9][11]:

  • Clean the vial stopper and skin with alcohol; allow to dry completely.
  • Pinch a skinfold; insert the needle at 90° (45° if very lean) into subcutaneous tissue[11].
  • Do not aspirate for subcutaneous injections; inject slowly and steadily over a few seconds[9].
  • Withdraw needle at the same angle; apply gentle pressure if bleeding occurs (do not rub).
  • Rotate sites systematically (abdomen at least 2 inches from navel, outer thighs, back of upper arms) to avoid irritation and lipohypertrophy[11].
  • Dispose of used syringes immediately in a proper sharps container (never reuse needles)[11].

Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. MOTS-c is an experimental compound for research use only. No clinical trials have been completed in humans. Always consult qualified healthcare providers before starting any new therapy.

References


  • Cell Metabolism (2015)
    — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (Lee C, Zeng J, Drew BG, et al.)
    View Source

  • Journal of Translational Medicine (2023)
    — Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging (Wan W, Zhang L, Lin Y, et al.)
    View Source

  • Journal of Molecular Medicine (2019)
    — MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction (Lu H, Wei M, Zhai Y, et al.)
    View Source

  • Nature Communications (2021)
    — MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis (Reynolds JC, Lai RW, Woodhead JST, et al.)
    View Source

  • Frontiers in Physiology (2023)
    — Role of MOTS-c in the regulation of bone metabolism (Yi X, Hu G, Yang Y, et al.)
    View Source

  • International Journal of Molecular Sciences (2022)
    — MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases (Mohtashami Z, Singh MK, Salimiaghdam N, et al.)
    View Source

  • Cognitive Vitality Reports (2021)
    — MOTS-c (Cognitive Vitality Profile) – Alzheimer’s Drug Discovery Foundation (ADDF)
    View Source

  • USADA Spirit of Sport (2023)
    — What is the MOTS-c peptide? – U.S. Anti-Doping Agency education article
    View Source

  • CDC Vaccine Administration Guidelines
    — Subcutaneous route technique (angle, site selection, no aspiration)
    View Source

  • Experimental & Molecular Medicine (2025)
    — Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes (Kong BS, Lee H, L’Yi S, et al.)
    View Source

  • MedlinePlus Medical Encyclopedia (2023)
    — Subcutaneous (SQ) injections – Patient instructions for proper technique
    View Source

  • Subcutaneous Drug Injection Review (PMC)
    — Literature review of factors influencing subcutaneous injection pharmacology
    View Source

  • Pure Lab Peptides
    — MOTS-C (10 mg) product page (quality and batch documentation)
    View Source